These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 38275876)
21. Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma. Shao G; Cui X; Wang Y; Luo S; Li C; Jiang Y; Cai D; Li N; Li X CNS Neurosci Ther; 2024 Jul; 30(7):e14791. PubMed ID: 38997808 [TBL] [Abstract][Full Text] [Related]
22. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics. Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292 [TBL] [Abstract][Full Text] [Related]
23. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma. Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817 [TBL] [Abstract][Full Text] [Related]
24. Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow-Derived Macrophages. Wu M; Wu L; Wu W; Zhu M; Li J; Wang Z; Li J; Ding R; Liang Y; Li L; Zhang T; Huang B; Cai Y; Li K; Li L; Zhang R; Hu B; Lin F; Wang X; Zheng S; Chen J; You Y; Jiang T; Zhang J; Chen H; Wang Q Cancer Res; 2023 Mar; 83(5):771-785. PubMed ID: 36622331 [TBL] [Abstract][Full Text] [Related]
25. Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822 [TBL] [Abstract][Full Text] [Related]
26. Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition. Rao R; Han R; Ogurek S; Xue C; Wu LM; Zhang L; Zhang L; Hu J; Phoenix TN; Waggoner SN; Lu QR Neuro Oncol; 2022 Apr; 24(4):584-597. PubMed ID: 34562087 [TBL] [Abstract][Full Text] [Related]
27. Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists. Broggi G; Angelico G; Farina J; Tinnirello G; Barresi V; Zanelli M; Palicelli A; Certo F; Barbagallo G; Magro G; Caltabiano R Pathol Res Pract; 2024 Feb; 254():155144. PubMed ID: 38277747 [TBL] [Abstract][Full Text] [Related]
28. Pericytes Are Immunoregulatory Cells in Glioma Genesis and Progression. Martinez-Morga M; Garrigos D; Rodriguez-Montero E; Pombero A; Garcia-Lopez R; Martinez S Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791110 [TBL] [Abstract][Full Text] [Related]
29. Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers? Giles B; Nakhjavani M; Wiesa A; Knight T; Shigdar S; Samarasinghe RM Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686652 [TBL] [Abstract][Full Text] [Related]
30. Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine. Martins C; Sarmento B Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1893. PubMed ID: 37186374 [TBL] [Abstract][Full Text] [Related]
31. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts. Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A Genome Med; 2024 Apr; 16(1):51. PubMed ID: 38566128 [TBL] [Abstract][Full Text] [Related]
32. Targeting the immune microenvironment for ovarian cancer therapy. Blanc-Durand F; Clemence Wei Xian L; Tan DSP Front Immunol; 2023; 14():1328651. PubMed ID: 38164130 [TBL] [Abstract][Full Text] [Related]
33. Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements. Fei X; Wu J; Tian H; Jiang D; Chen H; Yan K; Wang Y; Zhao Y; Chen H; Xie X; Wang Z; Zhu W; Huang Q Cancer Biomark; 2024; 41(1):1-24. PubMed ID: 39240627 [TBL] [Abstract][Full Text] [Related]
34. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma. Rivera M; Bander ED; Cisse B World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500 [TBL] [Abstract][Full Text] [Related]
35. Canine glioblastoma-derived extracellular vesicles as precise carriers for glioblastoma imaging: Targeting across the blood-brain barrier. Villa A; De Mitri Z; Vincenti S; Crippa E; Castiglioni L; Gelosa P; Rebecchi M; Tosi D; Brunialti E; Oevermann A; Falleni M; Sironi L; Bello L; Mazzaferro V; Ciana P Biomed Pharmacother; 2024 Mar; 172():116201. PubMed ID: 38306846 [TBL] [Abstract][Full Text] [Related]
36. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551 [TBL] [Abstract][Full Text] [Related]
37. Contemporary strategies in glioblastoma therapy: Recent developments and innovations. Khan M; Nasim M; Feizy M; Parveen R; Gull A; Khan S; Ali J Neuroscience; 2024 Nov; 560():211-237. PubMed ID: 39368608 [TBL] [Abstract][Full Text] [Related]
38. Local immunotherapy of glioblastoma: A comprehensive review of the concept. Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079 [TBL] [Abstract][Full Text] [Related]
39. Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies. Caverzán MD; Beaugé L; Oliveda PM; Cesca González B; Bühler EM; Ibarra LE Brain Sci; 2023 Mar; 13(4):. PubMed ID: 37190507 [TBL] [Abstract][Full Text] [Related]